Letters |

Candesartan vs Losartan and Mortality in Patients With Heart Failure

Norman Kaplan, MD
JAMA. 2011;305(15):1540-1542. doi:10.1001/jama.2011.463.
Text Size: A A A
Published online


To the Editor: The claim made in the study by Dr Eklind-Cervenka and colleagues1 that candesartan was associated with a lower mortality risk than losartan in patients with HF needs additional substantiation before it can be accepted as valid. The issue relates to the doses of losartan. A previous study reported a better outcome in patients with HF given 150 mg of losartan each day compared with those given 50 mg per day.2 The doses given to those receiving losartan were ambiguous in the study by Eklind-Cervenka et al. It appears that the dose was initially titrated to 50 mg and later in the trial to 150 mg, although a large percentage of patients did not receive the full dose at either time. The representation of doses and number of patients as shown in Table 2 are difficult to understand. Before a claim is made for the superiority of candesartan, the provision of a therapeutically equal dose of losartan will have to be shown.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




April 20, 2011
Friedrich Fruhwald, MD; Burkert Pieske, MD
JAMA. 2011;305(15):1540-1542. doi:10.1001/jama.2011.462.
April 20, 2011
Lars H. Lund, MD, PhD; Lina Benson, MSc; Maria Eklind-Cervenka, MD
JAMA. 2011;305(15):1540-1542. doi:10.1001/jama.2011.464.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.